Intratumoral Combinatorial Administration of CD1c (BDCA-1)
cancer immunotherapy
conventional dendritic cells
dendritic cells
immune checkpoint inhibitors
intratumoral
myeloid dendritic cells
tumor microenvironment
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
10 Nov 2020
10 Nov 2020
Historique:
received:
13
10
2020
revised:
05
11
2020
accepted:
06
11
2020
entrez:
13
11
2020
pubmed:
14
11
2020
medline:
14
11
2020
Statut:
epublish
Résumé
Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in re-licensing antitumor cytotoxic T lymphocytes. IT injection of the IgG
Identifiants
pubmed: 33182610
pii: vaccines8040670
doi: 10.3390/vaccines8040670
pmc: PMC7712037
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Kom op tegen Kanker
ID : 2016-128
Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Nat Commun. 2016 Dec 23;7:13720
pubmed: 28008905
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Clin Cancer Res. 2019 Jun 1;25(11):3469-3470
pubmed: 31160495
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Clin Cancer Res. 2016 May 1;22(9):2155-66
pubmed: 26712687
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768
pubmed: 27837020
Cancer Res. 2013 Feb 1;73(3):1063-75
pubmed: 23345163
Cancer Res. 2016 Aug 1;76(15):4332-46
pubmed: 27325645
PLoS One. 2016 Jun 16;11(6):e0157387
pubmed: 27311059
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
J Immunother Cancer. 2017 Feb 21;5:20
pubmed: 28239472
Blood. 2013 Aug 8;122(6):932-42
pubmed: 23794066
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer Immunol Immunother. 2015 Nov;64(11):1461-73
pubmed: 26275446
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Cancer Immunol Res. 2013 Sep;1(3):145-9
pubmed: 24777676
Cell. 2019 Apr 18;177(3):556-571.e16
pubmed: 30955881
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
J Immunother Cancer. 2019 Nov 14;7(1):302
pubmed: 31727154
Clin Cancer Res. 2013 Oct 1;19(19):5261-3
pubmed: 23965900
Cancer Immunol Res. 2015 Oct;3(10):1148-1157
pubmed: 26014098
J Immunother Cancer. 2015 Sep 15;3:43
pubmed: 26380088
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Oncotarget. 2016 Sep 27;7(39):64390-64399
pubmed: 27391442
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
J Immunother Cancer. 2019 Apr 18;7(1):109
pubmed: 30999964
Clin Cancer Res. 2013 Oct 1;19(19):5381-9
pubmed: 23788581
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Expert Opin Biol Ther. 2017 Apr;17(4):515-523
pubmed: 28274143
Oncoimmunology. 2016 Aug 03;5(8):e1192739
pubmed: 27622063
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023